Marco C Gymnopoulos

US Patent:

20110195111, Aug 11, 2011

Filed:

Dec 17, 2010

Appl. No.:

12/972089

Inventors:

B. Michael Butters - Lacey WA, US
John T. Butters - Del Mar CA, US
Christine Bonzon - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Mayra Montes Camacho - National City CA, US

Assignee:

NATIVIS, INC. - La Jolla CA

International Classification:

A61K 31/337
A61K 9/127
A61P 35/00
A61K 31/7105
C12N 5/09
G01J 3/44
G01J 3/00
G01R 33/12
B82Y 5/00

US Classification:

424450, 514449, 514 44 A, 435375, 356301, 356 51, 324228, 977773

Abstract:

A method of forming an aqueous composition effective to produce an agent-specific effect on an agent-responsive chemical or biological system, when the composition is added to the system, is disclosed. The composition is formed by exposing an aqueous medium to a low-frequency, time-domain signal derived from the agent, until the aqueous medium acquires a detectable agent activity. Exemplary compositions are formed by exposure to a paclitaxel signal or a signal derived from a therapeutic oligonucleotide, such as GAPDH antisense RNA and PCSK9 antisense RNA. Also disclosed are methods for confirming the activity of the composition, and for preparing and testing the activity of the compositions.

US Patent:

20220249679, Aug 11, 2022

Filed:

Oct 1, 2019

Appl. No.:

17/282368

Inventors:

- Osaka-Shi, Osaka, JP
Robyn RICHARDSON - San Diego CA, US
Anjuli TIMMER - San Diego CA, US
Roland NEWMAN - San Diego CA, US
Marco GYMNOPOULOS - San Diego CA, US

International Classification:

A61K 47/68
C07K 16/28

Abstract:

Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.

US Patent:

20210163604, Jun 3, 2021

Filed:

Mar 27, 2019

Appl. No.:

17/042013

Inventors:

- bsaka-shi, Osaka, JP
Marco GYMNOPOULOS - San Diego CA, US
Vincent BLOT - Seattle WA, US
Ryo FUJITA - Osaka-shi, Osaka, JP
Roland NEWMAN - San Diego CA, US

International Classification:

C07K 16/28
A61K 47/64
A61P 35/00
A61K 31/5517

Abstract:

Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.

US Patent:

20190330354, Oct 31, 2019

Filed:

Sep 28, 2017

Appl. No.:

16/334326

Inventors:

- Osaka, JP
Vincent BLOT - San Francisco CA, US
Marco GYMNOPOULOS - San Diego CA, US
Anjuli TIMMER - San Diego CA, US
Ryo FUJITA - Osaka, JP
Roland NEWMAN - San Diego CA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.

US Patent:

20180319885, Nov 8, 2018

Filed:

Nov 2, 2016

Appl. No.:

15/773167

Inventors:

- La Jolla CA, US
Feng Tian - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US

Assignee:

Ambrx, Inc. - La Jolla CA

International Classification:

C07K 16/28
A61K 47/68
A61K 31/522

Abstract:

Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.

US Patent:

20150152187, Jun 4, 2015

Filed:

Jun 14, 2013

Appl. No.:

14/407792

Inventors:

- La Jolla CA, US
Ning Zou - San Diego CA, US
Amha Hewet - Chula Vista CA, US
Jason K. Pinkstaff - San Rafael CA, US
Shailaja Srinagesh - San Mateo CA, US
Richard S. Barnett - San Marcos CA, US
Feng Tian - San Diego CA, US
Anna-Maria A. Hays Putnam - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Nick Knudsen - Escondido CA, US
Andrew Beck - San Diego CA, US

Assignee:

Ambrx, Inc. - La Jolla CA

International Classification:

C07K 16/30
A61K 47/48

Abstract:

This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

US Patent:

20150152190, Jun 4, 2015

Filed:

Jun 7, 2013

Appl. No.:

14/406190

Inventors:

- La Jolla CA, US
Feng Tian - San Diego CA, US
Anna-Maria A. Hays Putnam - San Diego CA, US
Marco Gymnopoulos - San Diego CA, US
Nick Knudsen - Escondido CA, US
Andrew Beck - San Diego CA, US
Ying Sun - San Diego CA, US

Assignee:

Ambrx, Inc. - La Jolla CA

International Classification:

C07K 16/40
C07K 7/06

Abstract:

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.